RGT Shares Argent BioPharma Limited
ASX · ASXLast in our picks 2026-10-05 — not in the current list; analysis below is from that screen
Small-cap hardware and technology exposure may benefit from niche semiconductor demand.
Signal breakdown
- ▸Liquidity and catalyst visibility appear limited versus top peers.
- ▾Below 50-day MA (-21.87%)
- ▾Near 52-week low (0% of range)
Is RGT a buy right now?
Trend: RGT is trading below the 50-day average (-16.67%), RSI 47 — neutral momentum, with a 3-month return of -37.50%.
Valuation & quality: fundamentals show net margin 0.0%.
Our screen: WATCH (score 0) — Small-cap hardware and technology exposure may benefit from niche semiconductor demand.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -33.30% | +0.00% | +0.00% | +0.00% | +0.00% | -25.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Semiconductors picks
Browse: all ASX stocks · Semiconductors picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.